Caris Life Sciences, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Caris Life Sciences announced a substantial 45.4% increase in total revenue for the second quarter of 2026, driven by molecular profiling services, alongside strategic product expansions.
NASDAQ
Caris Life Sciences reported strong Q1 2026 revenue growth to $216.2 million, driven by increased molecular profiling volumes.
NASDAQ
Caris Life Sciences reports a significant revenue increase and a return to net income in Q3 2025, driven by strong molecular profiling services and a successful IPO.
NASDAQ
Caris Life Sciences, a precision oncology pioneer, reported significant revenue growth in Q2 2025, driven by increased adoption of its molecular profiling services and a successful initial public offering.